Genmab A/S (GMAB) Expected to Release Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Genmab A/S to post earnings of $0.37 per share and revenue of $1.1110 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:00 PM ET.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $28.52 on Thursday. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. Genmab A/S has a 1-year low of $21.00 and a 1-year high of $35.43. The stock has a market capitalization of $17.78 billion, a P/E ratio of 21.61, a P/E/G ratio of 1.82 and a beta of 0.84. The business has a 50-day moving average price of $26.96 and a two-hundred day moving average price of $28.20.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on GMAB shares. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. HC Wainwright increased their price target on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.28.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently modified their holdings of the business. Orbis Allan Gray Ltd raised its holdings in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after buying an additional 3,340,456 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in shares of Genmab A/S by 84.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after buying an additional 3,222,983 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 5.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock worth $111,735,000 after acquiring an additional 188,761 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 23.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock worth $107,580,000 after acquiring an additional 671,307 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Genmab A/S by 9.5% during the fourth quarter. Morgan Stanley now owns 1,834,439 shares of the company’s stock worth $56,501,000 after acquiring an additional 159,865 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.